Table 4.

Cumulative effective dose (MSV) per person exposed during the period of study

Age at entry to study (years)	Total			Men			Women			P value
	Median	Percentile 25–75	Maximum	Median	Percentile 25–75	Maximum	Median	Percentile 25–75	Maximum
0–5	0.21	0.06–1.60	47.15	0.20	0.06–1.28	37.38	0.21	0.06–1.93	47.15	0.579
5–10	0.48	0.03–2.38	94.58	0.42	0.04–2.26	94.58	0.52	0.02–2.48	55.19	0.128
10–15	0.67	0.06–2.64	196.16	0.64	0.06–2.56	196.16	0.77	0.07–2.78	143.51	0.001
15–20	0.74	0.10–2.98	159.51	0.65	0.10–2.80	159.51	0.83	0.10–3.08	104.15	0.001
20–30	1.00	0.11–4.02	222.27	0.69	0.10–3.18	222.27	1.38	0.22–4.83	221.10	<0.001
30–40	1.23	0.38–5.75	297.14	1.09	0.16–5.14	297.14	1.29	0.38–6.04	259.56	0.002
40–50	2.00	0.38–10.12	716.16	2.03	0.30–10.87	389.44	1.96	0.38–9.70	716.16	0.417
50–60	4.27	0.64–17.08	629.58	4.17	0.62–18.05	629.58	4.32	0.65–16.26	430.68	0.514
60–70	8.35	1.47–25.72	506.08	9.80	1.47–29.21	506.08	7.63	1.48–23.46	489.57	<0.001
70–80	10.20	2.40–26.00	3980.30	12.05	2.60–30.46	502.08	8.81	2.18–23.21	3980.30	<0.001
>80	5.30	1.19–15.96	204.32	6.54	1.28–18.98	183.80	5.00	1.10–4.58	204.32	<0.001
Total	2.10	0.36– 10.15	3980.30	1.90	0.2– 10.20	629.58	2.38	0.38– 10.10	3980.30	< 0.001